Ajay K. Nooka, MD, MPH, FACP

home / authors / ajay-k-nooka-md-mph-facp

Articles

Ajay K. Nooka, MD, MPH, FACP

Dr Nooka on the Utility of Iopofosine I 131 in Waldenström Macroglobulinemia

Ajay K. Nooka, MD, MPH, FACP
April 3rd 2024

Ajay K. Nooka, MD, MPH, FACP, discusses the CLOVER-WaM trial of iopofosine I 131 for heavily pretreated, refractory Waldenström macroglobulinemia.

Read More

Site Logo

Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1

Ajay K. Nooka, MD, MPH, FACP
July 13th 2022

Dr Nooka reviews the patient reported outcomes from the MajesTEC-1 trial in patients with relapsed/refractory multiple myeloma.

Read More

Ajay K. Nooka, MD, MPH, FACP, of Emory University School of Medicine

Dr. Nooka on the Utility of BCMA as a Target in Multiple Myeloma

Ajay K. Nooka, MD, MPH, FACP
February 23rd 2021

Ajay K. Nooka, MD, MPH, FACP, discusses the utility of BCMA as a target in multiple myeloma.

Read More

Dr. Nooka on Treatment Options for Transplant-Eligible and -Ineligible Multiple Myeloma

Dr. Nooka on Treatment Options for Transplant-Eligible and -Ineligible Multiple Myeloma

Ajay K. Nooka, MD, MPH, FACP
November 14th 2019

Ajay K. Nooka, MD, MPH, FACP, discusses current options for transplant-eligible and -ineligible patients with multiple myeloma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data